Mr. Stephen Davis reports

FREQUENCY EXCHANGE CLOSES FINAL TRANCHE OF PRIVATE PLACEMENT

Further to its news releases dated July 21, 2025, Aug. 7, 2025, and Aug. 26, 2025, Frequency Exchange Corp. has closed the second and final tranche of its private placement.

In connection with the closing of the final tranche, the company issued an additional 3,418,031 units at a price of 25 cents per unit for proceeds of $854,507.75, bringing the total private placement to 7,352,133 units for aggregated proceeds of $1,838,033.25 when combined with the first-tranche closing.

Each unit consisted of one common share and one common share purchase warrant having an exercise price of 40 cents per warrant and a term of 24 months from the date of issuance. The warrants are subject to an acceleration clause, whereby, if the volume-weighted average trading price of the common shares on the TSX Venture Exchange is at least 70 cents per common share for any period of 10 consecutive trading days, the company may, at its sole option, accelerate the expiry date of warrants to the date that is not less than 21 days following the date upon which notice of the accelerated expiry date is provided by the company by way of news release.

The company issued 72,800 non-transferable finder warrants and paid a cash commission of $18,200 to Canaccord Genuity Corp. The finder warrants are at an exercise price of 40 cents per share for a period of 24 months from the date of issuance and are subject to the same acceleration clause as the warrants.

All securities issued in connection with the second tranche of the private placement are subject to a statutory hold period expiring Jan. 25, 2026.

The capital will be used to expand the company's team, cover general operating costs, provide a technology upgrade, pay down accrued debt, and support marketing initiatives in both the consumer and public markets. The capital will also be used to purchase increased inventory prompted by the greater demand following the expansion of Fremedica patented technology rights to include all general wellness markets for wearables for humans and animals around the world.

The private placement is subject to TSX-V final approval.

About Frequency Exchange Corp.

Based in British Columbia, Canada, Frequency Exchange is publicly traded under the trading symbols FREQ on the TSX-V and FRECF on the OTC (over-the-counter) market. Frequency Exchange acquired Fremedica Technologies Inc. in 2022. Fremedica is now a wholly owned and operating subsidiary of Frequency Exchange. Fremedica's business is focused on the development and global commercialization of Nikki, a wellness technology delivering frequency-enhanced wellness programs. Nikki means "victor of the people," bringing wellness programs to all walks of life. Fremedica began with the development of a specialized Lyme support program designed to help people struggling with Lyme disease. Now, Fremedica, through Nikki, delivers wellness programs to assist with issues including sleep, pain, energy, immunity and many more. Nikki delivers wellness programs to restore and improve communication in the network of trillions of cells that make up the human body. Strong cell communication is essential to good health.

Health can be disrupted by physical, mental and emotional trauma. For example, poor sleep can be a symptom of pain, stress and fatigue stemming from poor cell communication. Nikki delivers specific frequencies into the body for the purpose of restoring proper cell function. Categories of wellness programs continue to grow. The Nikki wellness technology, combined with frequency-based wellness programs, is the result of years of development and experimentation with advanced bioenergetic technology. In third party quality-of-life testing over an eight-week period, Nikki proved to provide an unprecedented level of benefits ranging from better sleep and reduced pain to less anxiety and greater energy, with 90 per cent of the test subjects experiencing improvement in overall wellness.

We seek Safe Harbor.